You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
 Sign up to receive our twice-weekly e-Newsletter  
 HIV and Hepatitis.com Coverage of the
60th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD 2009)
October 30 - November 3, 2009, Boston, MA
 The material posted on HIV and Hepatitis.com about AASLD 2009 is not approved by nor is it a part of AASLD 2009.
Library of Slides and Posters
  Hepatitis B Slides and Posters   (20)
  Hepatitis C Slides and Posters   (5)
  Hepatitis B and C Articles   (5)
  HIV-HCV and HIV-HBV Coinfection Articles   (1)


Hepatitis B - Library of Slides and Posters
A Phase 2, Double-Blind, Randomized Study Comparing The Safety of Tenofovir Disoproxil Fumarate (TDF), Emtricitabine Plus TDF (Truvada, TVD) and Entecavir (ETV) in Subjects with Decompensated Chronic Hepatitis B Liver Disease
Y Liaw and others. AASLD 2009.
Long-term Follow-up Evaluation of the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in a European Multicenter (Nucleos(t)ide Experienced) Hepatitis B Virus HBV-infected Cohort
F van Bömmel and others. AASLD 2009.
Parenchymal Fibrosis and Cancer Specific Outcomes Following Liver Resection in Patients with HBV Associated Hepatocellular Carcinoma
S Hiotis and others. AASLD 2009.
Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation
Y Liaw and others. AASLD 2009.
Tenofovir (TDF) Is Effective In Lamivudine (LAM) Resistant Chronic Hepatitis B Patients Who Harbour rtA194T At Baseline
S Fung and others. AASLD 2009.
Persistence and Adherence to Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
W Chotiyaputta and others. AASLD 2009.
Tenofovir Disoproxil Fumarate for patients with chronic hepatitis B who have previously failed Lamivudine and Adefovir: effects of baseline sequence mutations on virological response.
S Patterson and others. AASLD 2009.
In vitro susceptibility of HBV strains isolated from HIV-HBV Coinfected patients with delayed response to Tenofovir DF
O Lada and others. AASLD 2009.
Hepatitis B Virus (HBV) Transmission Rate among Children Born to Chinese-American Mothers with Chronic Hepatitis B (CHB) in the New York Downtown Area
L Mi and others. AASLD 2009.
Physician Country of Birth and Hepatitis B Virus (HBV) Screening Practices of Asian-American Primary Care Providers (PCPs) Who Treat Asian Adults Living in the US
T Tran and others. AASLD 2009.
Tenofovir Disoproxil Fumarate-Containing Regimens in Pregnancy: Report From the Antiretroviral Pregnancy Registry
R Brown and others. AASLD 2009.
Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With Chronic Hepatitis B (Study 103)
E Heathcote and others. AASLD 2009.
In Vitro Tenofovir Sensitivity of HBV Populations from Clinical Specimens Containing rtA181T/V and/or rtN236T
K Kitrinos and others. AASLD 2009.
Three Years Effi cacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B
S Lee and others. AASLD 2009.
Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102)
P Marcellin and others. AASLD 2009.
Prevalence and Characteristics of Hepatitis B Virus Mutations in Chronic Hepatitis B Patients on Oral Antiviral Therapy: The CHARM Study
S Roberts and others. AASLD 2009.
Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase
A Snow-Lampart and others. AASLD 2009.
Loss of HBsAg in Nucleoside-Naïve HBeAg(+) Chronic Hepatitis B Patients Following Treatment with Entecavir or Lamivudine: Evaluation of HBV Genotypes
R Gish and others. AASLD 2009.
Adherence to AASLD Guideline Recommendations for Laboratory Monitoring of Chronic Hepatitis B Patients Who are Not Receiving Antiviral Treatment
T Juday and others. AASLD 2009.
Diagnosis and Management of Chronic Hepatitis B in Asian-American Patients Among Primary Care Physicians in the United States
N Upadhyaya and others. AASLD 2009.
 

Hepatitis C - Library of Slides and Posters
SILEN-C1: Early Antiviral Activity and Safety of BI 201335 Combined with Peginterferon alfa-2a and Ribavirin in Treatment-naïve Patients with Chronic Genotype 1 HCV infection
M Sulkowski and others. AASLD 2009.
Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin
E Pol and others. AASLD 2009.
Response-Guided Therapy for Boceprevir Combination Treatment? Results from HCV SPRINT-1
P Kwo and others. AASLD 2009.
Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study
M Manns and others. AASLD 2009.
High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon á-2b + Ribavirin When Treated with Boceprevir Combination Therapy Results From HCV Sprint-1
P Kwo and others. AASLD 2009.
Once Daily Narlaprevir (SCH 900518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study
J Vierling and others. AASLD 2009.
Synergistic effect of obesity and alcohol on the risk of hepatocellular carcinoma in men: a prospective cohort study
R Loomba and others. AASLD 2009.
 

Hepatitis B and C Articles
Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
Review Finds Pegylated Interferon Is More Effective than Lamivudine for Chronic Hepatitis B, but Study Shows Little Activity against HBV Genotype D
Early HBsAg Decline Predicts Sustained Response to Pegylated Interferon; Extended Treatment Can Improve Outcomes
Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
Oral HCV Protease Inhibitor R7227 plus Polymerase Inhibitor R7128 Suppresses HCV Viral Load without Interferon or Ribavirin
Entecavir (Baraclude) and Tenofovir (Viread) Rescue Therapy for Chronic Hepatitis B Patients with Advanced Fibrosis and Prior Treatment Failure
HCV Protease Inhibitor Telaprevir Demonstrates Good Efficacy in Both Treatment-experienced and Treatment-naive Patients
Boosted Narlaprevir plus Pegylated Interferon and Ribavirin Leads to Rapid Viral Suppression in Genotype 1 Hepatitis C Patients
Nitazoxanide plus Pegylated Interferon and Ribavirin Produces Virological Response in Some Prior Non-responders with Cirrhosis
High HBV Viral Load and Being HBeAg Positive Are Associated with Decreased Life Expectancy for People with Hepatitis B
SPRINT-1 Study Shows Benefits of Response-guided Therapy with Experimental HCV Protease Inhibitor Boceprevir
Experimental HCV Protease Inhibitor BI 201335 Demonstrates Promising Results in Combination with Pegylated Interferon and Ribavirin
Tenofovir (Viread) Regimens Are Effective and Well-tolerated in Chronic Hepatitis B Patients with Decompensated Liver Disease
Long-term Studies Show Tenofovir (Viread) Safety and Efficacy Is Sustained at 3 Years in HBeAg Positive and Negative Hepatitis B Patients
Entecavir (Baraclude) Demonstrates Greater Antiviral Activity than Adefovir (Hepsera) in Hepatitis B Patients with Decompensated Liver Disease
Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
Liver Transplant Outcomes Have Improved over Time for Patients with and without Hepatitis C
AASLD Liver Meeting Starts Today in Boston

HIV/HCV and HIV/HBV Coinfection Articles
Study Looks at Factors Affecting Survival of HIV/HCV Coinfected Liver Transplant Recipients
Rapid Liver Fibrosis Progression and Successful Treatment of Acute Infection Suggest Benefits of Routine HCV Screening for HIV Positive Men
Rapid Liver Fibrosis Progression and Successful Treatment of Acute Infection Suggest Benefits of Routine HCV Screening for HIV Positive Men
New HCV Infection Is Occurring among HIV Positive U.S. Men, ACTG Analysis Shows
Tenofovir (Viread) Suppresses HBV Viral Load Long-term in HIV/HBV Coinfected Patients, but Kidney Function May Decline
 
   
   
   
   
   
   
   
   
   
   
   
  AASLD 2009 Coverage - HIV and Hepatiits.com Coverage of AASLD 2009
   
   
   
   
   
   
   
  AASLD 2009 Coverage - HIV and Hepatiits.com Coverage of AASLD 2009
 

 

 

 


 Google Custom Search


































































































 
HIV and Hepatitis.com is published by HIV and Hepatitis Treatment Advocates, Inc.